Preclinical studies in animal models have suggested that GLP-1 receptor agonists may: Promote neuronal survival and reduce neuroinflammation Enhance synaptic plasticity , which is crucial for learning and memory formation Reduce amyloid plaque formation and tau protein phosphorylation, pathological hallmarks of Alzheimer's disease Improve cerebral blood flow and reduce oxidative stress in brain tissue Several clinical trials are currently investigating GLP-1 receptor agonists for neurodegenerative conditions, including Alzheimer's disease and Parkinson's disease
dos Santos Ribeiro et al., 2021)
[DOI] [PMC free article] [PubMed] [Google Scholar] 59.Mollica J.P., Dutka T.L., Merry T.L., Lamboley C.R., McConell G.K., McKenna M.J., Murphy R.M., Lamb G.D
They analyzed how this variant influenced various forms of lean mass, including appendicular lean mass, total fat-free mass, and trunk fat-free mass
They include recommendations to consider sleep quality and food access, screen for a history of disordered eating, to take the person's whole health into account rather than just their metabolic health and to encourage strength training to build and maintain muscle mass